An outline of ImmunoSABR papers, abstracts and reviews.
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).
Authors : Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois & Philippe Lambin
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.
Authors : Relinde I. Y. Lieverse Damiënne Marcus Alexander M. A. van der Wiel Evert J. Van Limbergen Jan Theys Ala Yaromina Philippe Lambin Ludwig J. Dubois
Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy
Authors : PhilippeLambin MD PhD, Relinde I.Y.Lieverse MD, Franziska Eckert MD , Damiënne Marcus MSc, Cary Oberije PhD, Alexander M.A.van der Wiel MSc, Chandan Guha MD PhD, Ludwig J. Dubois PhD , Joseph O. Deasy PhD
Will immunotherapy really change radiotherapy?
Our opinion is to redesign a new framework in a way radiotherapy is delivered to interact most optimally with immunotherapy rather than directly killing as many cells as possible with radiation.
Authors : Philippe Lambin, Relinde Lieverse
How Advances in Imaging Will Affect Precision Radiation Oncology.
Int J Radiat Oncol Biol Phys. 2018 Jun 1
Authors : Jaffray DA, Das S, Jacobs PM, Jeraj R, Lambin P.
Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer.
Radiol Med. 2018 Apr
Authors : Cusumano D, Dinapoli N, Boldrini L, Chiloiro G, Gatta R, Masciocchi C, Lenkowicz J, Casà C, Damiani A, Azario L, Van Soest J, Dekker A, Lambin P, De Spirito M, Valentini V.
Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.
Acta Oncol. 2018 Apr
Authors : Ureba A, Lindblom E, Dasu A, Uhrdin J, Even AJG, van Elmpt W, Lambin P, Wersäll P, Toma-Dasu I.
Multi-Scale Modeling and Oxygen Impact on Tumor Temporal Evolution: Application on Rectal Cancer During Radiotherapy.
IEEE Trans Med Imaging. 2018 Apr
Authors : Apeke S, Gaubert L, Boussion N, Lambin P, Visvikis D, Rodin V, Redou P.
Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study.
Br J Radiol. 2018 Mar
Authors : Leijenaar RT, Bogowicz M, Jochems A, Hoebers FJ, Wesseling FW, Huang SH, Chan B, Waldron JN, O’Sullivan B, Rietveld D, Leemans CR, Brakenhoff RH, Riesterer O, Tanadini-Lang S, Guckenberger M, Ikenberg K, Lambin P.
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study.
PLoS One. 2018 Mar 1
Authors : Carvalho S, Leijenaar RTH, Troost EGC, van Timmeren JE, Oberije C, van Elmpt W, de Geus-Oei LF, Bussink J, Lambin P.
A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.
Acta Oncol. 2018 Feb
Authors : Jochems A, El-Naqa I, Kessler M, Mayo CS, Jolly S, Matuszak M, Faivre-Finn C, Price G, Holloway L, Vinod S, Field M, Barakat MS, Thwaites D, de Ruysscher D, Dekker A, Lambin P.
Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review.
Seizure. 2018 Feb
Authors : Eekers DBP, Pijnappel EN, Schijns OEMG, Colon A, Hoeben A, Zindler JD, Postma AA, Hoffmann AL, Lambin P, Troost EGC.
Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability.
Cancers (Basel). 2018 Feb 18
Authors : Walsh S, Roelofs E, Kuess P, van Wijk Y, Vanneste B, Dekker A, Lambin P, Jones B, Georg D, Verhaegen F.
Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms.
Oncotarget. 2018 Feb 15
Authors : Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D.
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.
Oncoimmunology. 2018 Jan 16
Authors : Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, Germeraad WTV, Van Limbergen EJ, Neri D, Dubois LJ, Lambin P
Novel tools to assist neoepitope targeting in personalized cancer immunotherapy.
Ann Oncol. 2017 Dec 1
Authors : Saini SK, Rekers N, Hadrup SR
The posterior cerebellum, a new organ at risk?
Clin Transl Radiat Oncol. 2017 Nov
Authors : Eekers DBP, In ‘t Ven L, Deprez S, Jacobi L, Roelofs E, Hoeben A, Lambin P, de Ruysscher D, Troost EGC.
Combining radiotherapy with immunotherapy: the past, the present and the future.
Br J Radiol. 2017 Aug
Authors : Van Limbergen EJ, De Ruysscher DK, Olivo Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ, Lambin P
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres’ organisation.
Ecancermedicalscience. 2016 Nov 10
Authors : Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.
Radiother Oncol. 2015 Sep
Authors : Rekers NH, Zegers CM, Yaromina A, Lieuwes NG, Biemans R, Senden-Gijsbers BL, Losen M, Van Limbergen EJ, Germeraad WT, Neri D, Dubois L, Lambin P
Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
Clin Cancer Res. 2015 Mar 1
Authors : Zegers CM, Rekers NH, Quaden DH, Lieuwes NG, Yaromina A, Germeraad WT, Wieten L, Biessen EA, Boon L, Neri D, Troost EG, Dubois LJ, Lambin P
Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.
Cancer Radiother. 2014 Oct
Authors : Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P
STAY INFORMED ?
If you want to stay informed about ImmunoSABR project, please subscribe to our newsletter.
The D-Lab / Precision Medicine
P.O. Box 616,
6200 MD Maastricht, The Netherlands
This project has received funding from the European Union’s. Horizon 2020 research and innovation programme under grant agreement No 733008